Last fall, 57-year-old Curt Krouse became the first Penn Medicine patient outside a clinical trial to receive the first FDA-approved gene therapy for adults with hemophilia B—with the promise of curing his rare bleeding disorder. “It is hard to explain the feeling,” Krouse said. “[Now] I bang my arm or scratch my leg and instead of infusing, I just watch the affected area clot normally. It’s like a science fiction movie, but it’s real.” Link in bio for the full story. #hemophilia #hemophiliab #genetherapy